Rob recently joined Adaptive Biotechnologies as a Clinical Lab Director to pursue molecular pathology practice in the genomics era. He was previously Director of Corporate and Venture Development at Illumina from 2011-2016, where he focused on diagnostics development partnerships. He left that role to complete a Molecular Genetic Pathology fellowship at Cedars-Sinai Medical Center in Los Angeles, while continuing as a consultant for Illumina Ventures.
Prior to Illumina, Rob worked in the corporate venture unit of Biogen Idec, Inc., in San Diego, where he evaluated investment opportunities in early-stage cancer therapeutics. From 1992-2006, he was a research scientist at two biotech subsidiaries of Schering-Plough Corp. His laboratory work included cancer genetics, tumor suppressor genes, prostate cancer, cancer gene therapy, and cancer drug discovery.
Rob completed a residency and research fellowship in the Department of Pathology at University of California, San Diego (UCSD). He is a graduate of Yale University School of Medicine (1984) and UCSD’s Revelle College (Biology, 1979).